NPR logo

Novartis Loses Patent Battle In India

  • Download
  • <iframe src="https://www.npr.org/player/embed/175891880/175891994" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Novartis Loses Patent Battle In India

Business

Novartis Loses Patent Battle In India

Novartis Loses Patent Battle In India

  • Download
  • <iframe src="https://www.npr.org/player/embed/175891880/175891994" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent a new version of a cancer drug. It's a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines.

STEVE INSKEEP, HOST:

NPR's business news starts with a patent ruling that may affect millions.

(SOUNDBITE OF MUSIC)

INSKEEP: The ruling comes from the supreme court of India, a country with a population somewhere north of a billion. The Indian supreme court rejected patent rights claimed by the pharmaceutical giant Novartis. This ruling opens the door for Indian drug makers to produce generic versions of Novartis' lifesaving cancer drugs and will make the medicine more affordable for people in developing nations.

Copyright © 2013 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

We no longer support commenting on NPR.org stories, but you can find us every day on Facebook, Twitter, email, and many other platforms. Learn more or contact us.